LCM QSP™ (COMING SOON!)

Highlights:

  • LCM QSP™: Longitudinal Capillary Multiomics with Quantitative Systems Pharmacology™
  • Patient-specific CSCR™ followed by LCM™ was deployed for modeling and simulation (M&S) for quantitative systems pharmacology (QSP) to understand drug mechanism of action (MoA), in vitro physiology and putative clinical outcomes.
  • Proximal PK and PD effects for novel pharma screened assets were computationally derived via LCM QSP™ for preclinical and discovery stages to support promising and optimal lead selection.
  • Preclinical models start with patient-specific capillary blood collections via LCM™, whereby downstream computational PKPD and QPS modeling occurs via CSCR™.
  • Preclinical in vitro LCM QPS™ models calculate risks and assumptions that can translate to FIH data.
  • PKPD assessments for dose-finding, safety, efficacy, MoA, therapeutic index, and toxicity windows can be modeled beforehand for patient-specific in vitro predictions.
  • Simulation for putative doses, mechanistic modeling, and safety and efficacy effects for potential AEs can be predicted.

*Currently under R&D. 

Want the white paper? Contact us below!